Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Shadia Nada¹, Farouk Abu Alhana², Yongqing Wang², Nezam Altorok³ and Bashar Kahaleh⁴, ¹Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ²The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…
Abstract Number: 2256 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics, Laboratory Findings and Nailfold Capillaroscopy Microscopy Patterns in a Monocentric Series of 123 Patients with Idiopathic Pernio
Thi Phuong Uyen Doan¹, Sara Hussein¹, Martial Koenig² and France Joyal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Few studies have looked at the characteristics of patients diagnosed with pernio and the significance of the use of capillaroscopy in these patients. The…
Abstract Number: 2379 • 2015 ACR/ARHP Annual Meeting
Clinical Follow-up Predictors of Disease Pattern Change in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International and Retrospective Study
Franco Franceschini¹, Elena Bartoloni-Bocci², Santos Castañeda³, Laura Nuno⁴, Carlo Alberto Scirè⁵, Francisco Javier López-Longo⁶, Julia Martínez-Barrio⁷, Ilaria Cavazzana¹, Paolo Airò⁸, Javier Bachiller Corral⁹, Alberto Sifuentes Giraldo¹⁰, Rossella Neri¹¹, Simone Barsotti¹², Roberto Caporali¹³, Carlomaurizio Montecucco¹⁴, Marcello Govoni¹⁵, Renato La Corte¹⁵, Federica Furini¹⁵, Florenzo Iannone¹⁶, Margherita Giannini¹⁷, Enrico Fusaro¹⁸, Simone Parisi¹⁹, Giuseppe Paolazzi²⁰, Giovanni Barausse²¹, Raffaele Pellerito²², Alessandra Russo²², Lesley Ann Saketkoo²³, Norberto Ortego-Centeno²⁴, Luca Quartuccio²⁵, Christof Specker²⁶, Andreas Schwarting²⁷, Kostantinos Triantafyllias²⁸, Carlo Selmi²⁹, Fausto Salaffi³⁰, Marco Amedeo Cimmino³¹, Annamaria Iuliano³², Fabrizio Conti³³, Gianluigi Baiocchi³⁴, Elena Bravi³⁵, Anna Ghirardello³⁶, Trinitario Pina³⁷, Miguel A. Gonzalez-Gay³⁸, Lorenzo Cavagna³⁹ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹²Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹³University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹⁵UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁷DIM, Rheumatology Unit, Bari, Italy, ¹⁸Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁹Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ²⁰Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²¹Rheumatology, Ospedale di Trento, Trento, Italy, ²²Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²³New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Tulane University Lung Center, New Orleans, LA, ²⁴Hospital San Cecilio. Granada, Granada, Spain, ²⁵S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²⁶Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁷Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁸ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ³⁰Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ³¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³²Osp. San Camillo, Roma, Italy, ³³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³⁴Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³⁵Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁶Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁸Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ³⁹Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) constitute the classic clinical triad of antisynthetase syndrome (ASSD). Even if reported in up to 90% of…
Abstract Number: 2909 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus
Jennifer Medlin¹, Karen E. Hansen², Sara Fitz³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Rheumatology/Medicine, Univ of Wisconsin, Madison, WI, ³Department of Dermatology, Mercy Medical Center, Dubuque, IA, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is commonly diagnosed in females of reproductive age, with those diagnosed after the age of 50 referred to as…
Abstract Number: 2963 • 2015 ACR/ARHP Annual Meeting
Correlations Between Microvasculature Changes and Angiogenic Factors in Systemic Sclerosis – Data from a Single Center Registry
Radim Becvar¹, Simona Skacelova², Jiri Stork³, Hana Hulejová⁴, Ivana Putova⁵, Michal Tomcik⁶ and Marie Jachymova⁷, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Clinic of Dermatology and Venerology, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology of the 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁷Second Internal Clinic – Clinic of Cardiology and Angiology, General University Hospital,, Prague, Czech Republic
Background/Purpose: Histopathological hallmarks of systemic sclerosis (SSc) are perivascular infiltrates and a reduced capillary density, which precede the excessive accumulation of extracellular matrix components in…
Abstract Number: 2970 • 2015 ACR/ARHP Annual Meeting
Primary Care Assessment of Capillaroscopy Abnormalities in Patients with Raynaud’s Phenomenon
Rebecca Overbury¹, Maureen Murtaugh², Aryeh Fischer³ and Tracy M. Frech⁴, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³University of Colorado School of Medicine, Aurora, CO, ⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Raynaud’s phenomenon is a clinical symptom that can commonly present to a primary care provider or generalist. Proper identification of an underlying connective tissue…
Abstract Number: 2977 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis of Phosphodiesterase 5 Inhibitors for the Treatment of Raynaud’s Phenomenon
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Jordi Pardo⁶, Elizabeth Ghogomu⁷, Peter Tugwell⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁸Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of phosphodiesterase 5 inhibitors (PDE5) for the treatment of Raynaud's phenomenon (RP).Methods: The Cochrane library, MEDLINE, EMBASE and Clinicaltrials.gov…
Abstract Number: 2982 • 2015 ACR/ARHP Annual Meeting
Blood Perfusion in Different Skin Areas of Hands in Primary Raynaud’s Phenomenon and Systemic Sclerosis Patients
Alberto Sulli¹, Barbara Ruaro¹, Amelia Chiara Trombetta¹, Vanessa Smith², Carmen Pizzorni¹, Sabrina Paolino¹ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: Peripheral blood perfusion is reduced in patients affected by both primary (PRP) or secondary Raynaud’s phenomenon (SRP) (1-2). The objective of this study was…
Abstract Number: 3007 • 2015 ACR/ARHP Annual Meeting
Cold Receptor Expression and Function in Human Dermal Fibroblast: Possible Role in the Pathogenesis of Scleroderma Fibrosis
Yongqing Wang¹, John Sun¹, Shadia Nada², Nezam Altorok³ and Bashar Kahaleh⁴, ¹The University of Toledo, Toledo, OH, ²Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Enhanced cold sensitivity is an early and consistent phenomenon in scleroderma (SSc). We previously demonstrated increased expression of the transient receptor potential melastatine 8…
Abstract Number: 638 • 2015 ACR/ARHP Annual Meeting
Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach
Natsumi Ikumi¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Hirotake Inomata⁴, Yosuke Nagasawa⁴, Kaita Sugiyama⁴, Hiromi Karasawa¹, Takamasa Nozaki⁴, Hidetaka Shiraiwa⁴, Mitsuhiro Iwata², Noboru Kitamura⁵, Yoshihiro Matsukawa¹ and Masami Takei², ¹Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Nihon University School of Medicine, Tokyo, Japan, ⁵NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren syndrome (pSS) shares many clinical, inflammatory, and immunological features with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). SLE and RA are…
Abstract Number: 822 • 2015 ACR/ARHP Annual Meeting
Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
Sei-ichiro Motegi¹, Kazuya Yamada¹, Sayaka Toki¹, Akihiko Uchiyama¹, Tetsuya Nakamura² and Osamu Ishikawa¹, ¹Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan, ²Clinical Investigation and Research Unit, Gunma University Graduate School of Medicine, Gunma, Japan
Background/Purpose: Systemic scleroderma (SSc) is a generalized connective tissue disease characterized by fibrosis of the skin and internal organs, vascular dysfunction and immune disorder. Patients…
Abstract Number: 3004 • 2014 ACR/ARHP Annual Meeting
Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease
Dana P. Ascherman^1,2, Yunjuan Zang³, Laisel Martinez⁴, Judith Pignac-Kobinger⁵, Irina Fernandez³ and Eric L. Greidinger^3,4, ¹Medicine/Rheumatology, University of Miami, Miami, FL, ²Rheumatology, Miami VAMC, Miami, FL, ³Rheumatology, University of Miami, Miami, FL, ⁴Miami VAMC, Miami, FL, ⁵University of Miami, Miami, FL
Background/Purpose: Raynaud’s Phenomenon (RP) is frequently seen in autoimmune conditions, but an autoimmune basis for RP has not been established. Methods: Sera derived from anti-RNP+…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].